Posit Science's BrainHQ Training Shows 25% Reduction in Alzheimer’s Risk in Long-Term Study

Event summary

  • The NIH-funded ACTIVE Study found that Posit Science’s BrainHQ speed-of-processing training reduced Alzheimer’s risk by 25% over 20 years.
  • The study involved 2,800 participants and compared BrainHQ’s Double Decision exercise to memory and reasoning training.
  • Posit Science’s CEO, Dr. Henry Mahncke, attributed the results to decades of research on brain plasticity and acetylcholine upregulation.
  • BrainHQ is available in 13 languages and costs $96 per year, with over 300 studies supporting its cognitive benefits.

The big picture

Posit Science’s results align with growing interest in non-pharmacological interventions for cognitive decline, particularly as global dementia cases rise. The study’s long-term validation of BrainHQ’s speed-of-processing training could reshape preventive healthcare strategies, positioning Posit Science as a key player in brain health innovation. The broader industry is watching whether these findings will drive insurance coverage and broader clinical adoption.

What we're watching

Market Adoption
The pace at which BrainHQ gains traction among health plans, medical centers, and consumers following these study results.
Competitive Positioning
Whether Posit Science can leverage these findings to differentiate itself in the crowded brain-training market.
Regulatory Validation
How regulatory bodies may respond to these findings and whether they could accelerate approvals for similar interventions.

Related topics

Biotechnology